

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5118607

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
JENS FILIP ANDREAS RICHTER	08/08/2018
KERSTIN ELSA MARIA JOHNSON	08/08/2018
ERIK KONRAD GJERTSSON	08/13/2018
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	EXINI DIAGNOSTICS AB
<b>Street Address:</b>	IDEON SCIENCE PARK
<b>Internal Address:</b>	SCHEELEVÄGEN 27, GATEWAY
<b>City:</b>	LUND
<b>State/Country:</b>	SWEDEN
<b>Postal Code:</b>	SE-223 70
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	16003006
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(617)502-5002
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	617-248-5000
<b>Email:</b>	PatentDocket@choate.com
<b>Correspondent Name:</b>	CHOATE HALL & STEWART LLP-PATENT DOCKET
<b>Address Line 1:</b>	TWO INTERNATIONAL PLACE
<b>Address Line 4:</b>	BOSTON, MASSACHUSETTS 02110
<b>ATTORNEY DOCKET NUMBER:</b>	2010358-0049
<b>NAME OF SUBMITTER:</b>	RONEN ADATO, PHD
<b>SIGNATURE:</b>	/Ronen Adato/
<b>DATE SIGNED:</b>	08/30/2018
This document serves as an Oath/Declaration (37 CFR 1.63).	
<b>Total Attachments: 8</b>	
source=EXI-007US Assignment - Exini#page1.tif	

source=EXI-007US Assignment - Exini#page2.tif  
source=EXI-007US Assignment - Exini#page3.tif  
source=EXI-007US Assignment - Exini#page4.tif  
source=EXI-007US Assignment - Exini#page5.tif  
source=EXI-007US Assignment - Exini#page6.tif  
source=EXI-007US Assignment - Exini#page7.tif  
source=EXI-007US Assignment - Exini#page8.tif

**COMBINED JOINT ASSIGNMENT & DECLARATION****A. ASSIGNMENT**

WHEREAS, each of the below-named inventors whose name and residence is set forth in the following Table 1:

<b>Inventor Name</b>	<b>City, State</b>
<b>1. Karl Vilhelm Sjöstrand</b>	New York, New York
<b>2. Jens Filip Andreas Richter</b>	Lund, Sweden
<b>3. Kerstin Elsa Maria Johnsson</b>	Lund, Sweden
<b>4. Erik Konrad Gjertsson</b>	Lund, Sweden

Table 1

hereby declares and agrees, on behalf of himself/herself and all of his/her successors and assigns that each is aware of the patent application(s) entitled:

**SYSTEMS AND METHODS FOR RAPID NEURAL NETWORK-BASED IMAGE SEGMENTATION AND RADIOPHARMACEUTICAL UPTAKE DETERMINATION;**  
and

☐ prepared for filing in the United States Patent and Trademark Office; or

☒ identified by United States Application No. 16/003006  
filed in the United States Patent and Trademark Office on June 7, 2018; and

☐ identified by International Patent Application No. \_\_\_\_\_  
filed on \_\_\_\_\_; and

☒ and is also aware of the following priority applications:

<b>Application No.</b>	<b>Filed</b>
62/614935	January 8, 2018

WHEREAS, **EXINI Diagnostics AB** (hereinafter "ASSIGNEE"), a wholly-owned subsidiary of Progenics Pharmaceuticals, Inc., said ASSIGNEE having a usual place of business at **Ideon Science Park, Scheelevägen 27, Gateway, SE-223 70 Lund, SWEDEN**, desires to acquire or confirm an interest therein;

NOW, THEREFORE, to all whom it may concern be it known that, in consideration of agreements previously and duly entered into between the parties, **(i) inventors Jens Filip Andreas Richter, Kerstin Elsa Maria Johnsson, and Erik Konrad Gjertsson, and (ii)**

**ASSIGNEE (EXINI Diagnostics AB)**, and/or for other good and valuable consideration, the receipt of which is hereby acknowledged, each of us has sold, assigned, and transferred and/or do hereby sell, assign, and transfer unto said ASSIGNEE, its successors, assigns, and legal representatives, my entire right, title, and interest in and throughout the United States of America, its territories and all foreign countries, in and to any and all inventions described in the patent application, and/or any priority applications noted above, including any right of priority thereto; and hereby confirm that my sale, assignment and transfer is and was effective at least as of the filing date of the patent application and/or priority application. Our sale, assignment and transfer applies to the above-referenced patent application, and to any application that is based in whole or in part on the patent application, including any divisional, continuing, substitute, renewal, reissue, reexamination and other applications, for example that claim priority to the patent application. Also, this sale, assignment and transfer pertains to any and all other rights arising under or pursuant to any and all international agreements, treaties, or laws relating to the protection of industrial property, including all rights of priority under the International Convention for the Protection of Industrial Property, and in and to any such patent(s) as may issue thereon including any and all original and reissued patents which have been or shall be issued in the United States and foreign countries; said inventions, applications, and patent(s) to be held and enjoyed by ASSIGNEE for its own use and for its successors, assigns and legal representatives, to the full end of the term for which said patent(s) may be granted as fully and entirely as the same would have been held by each of us had this sale, assignment and transfer not been made;

AND, each of us hereby acknowledges that this Assignment, being of our entire right, title, and interest in and to the inventions, carries with it the right in ASSIGNEE, by attorneys and agents of ASSIGNEE selection, to apply for and receive any and all patent(s) for said inventions in its own name;

AND, each of us hereby further agrees for ourselves and our executors and administrators to execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the patent(s) to ASSIGNEE, its successors, assignees, and legal representatives, but at its expense and charges, including the execution of application for patents in foreign countries, the execution of substitution, reissue, divisional or continuation applications, and the giving of testimony, preliminary statements, or other statements in any interference or other proceeding in which the inventions or any applications or patents directed to the inventions may be involved by communicating to the ASSIGNEE all facts we know relating to the inventions and their history, and generally by doing everything possible which ASSIGNEE shall consider desirable for aiding in securing and maintaining proper patent protection for the inventions and for vesting title in the inventions and all applications for patent and all patents on the inventions in ASSIGNEE;

AND, each of us further hereby authorizes ASSIGNEE or its attorneys or agents to insert the correct application number(s) and/or filing date(s) into this assignment document, if appropriate;

AND, each of us hereby appoints ASSIGNEE as our common agent for purposes of prosecuting international patent applications and any national patent applications for which such common agency is recognized;

AND, each of us hereby requests the Commissioner for Patents of the United States Patent and Trademark Office to issue any and all patent(s) as shall be granted upon said application or applications based thereon to ASSIGNEE, its successors, assigns, and legal representatives;

AND, each of us covenants with said ASSIGNEE that no assignment, grant, mortgage, license, or other agreement affecting the rights and property herein conveyed has been made to others by us, and that full right to convey the same as herein expressed is possessed by us.

**B. DECLARATION (37 CFR 1.63)**

As below named inventors, we hereby declare that:

This declaration is directed to the patent application entitled:

**SYSTEMS AND METHODS FOR RAPID NEURAL NETWORK-BASED IMAGE  
SEGMENTATION AND RADIOPHARMACEUTICAL UPTAKE DETERMINATION;  
and**

☐ attached hereto or prepared for filing in the United States Patent and Trademark  
Office; or

☒ identified by United States Application No. 16/003006  
filed in the United States Patent and Trademark Office on June 7, 2018; or


☐ identified by International Patent Application No. \_\_\_\_\_  
filed on \_\_\_\_\_.

The above-identified application was made or authorized to be made by us.

We believe that we are each an original joint inventor of a claimed invention in the  
application.

We hereby acknowledge that any willful false statement made in this declaration is  
punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or  
both.

We have reviewed and understand the contents of the application, including the claims  
and are aware of the duty to disclose to the United States Patent and Trademark Office all  
information known to be material to patentability as defined in 37 CFR 1.56.

Signature:   
Jens Filip Andreas Richter

Date: 2018-08-08

Witness Signature: 


Witness Name (printed): Jonny J. Sandgreen

Witness Signature: 


Witness Name (printed): Assem Anand

Signature:   
Kerstin Elsa Maria Johansson

Date: 2018-08-28


Witness Signature: 


Witness Name (printed): MICHAEL KOBER


Witness Signature: 

Witness Name (printed): JENNY SANDOZ



Signature:  Date: 2018-08-13  
Erik Konrad Gjertsson

Witness Signature:   
Witness Name (printed): JENNY S. JACOBSEN

Witness Signature:   
Witness Name (printed): Ulf Mathsson

The undersigned (whose title is supplied below) is authorized to act on behalf of EXINI  
Diagnostics AB.

Signature:  Date: 2018-08-08

Name (printed): ASGER ANAND

Title (printed): SITE MANAGER